Australian research has, for the first time, demonstrated the therapeutic advantages of hypofractionated radiotherapy (RT) in early-stage prostate cancer.
In nearly 220 patients with localised carcinoma of the prostate, the South Australian-led researchers assessed the efficacy and toxicity of hypofractionated RT (55 Gy in 20 fractions within 4 weeks) compared with conventional RT (64 Gy in 32 fractions within 6.5 weeks).
Four years into the trial the radiooncology department acquired 3D conformal RT capability. Patients included in this subgroup (n=61) were still randomised to receive either hypofractionated or conventional RT.
The results, published in the International Journal of Radiation Oncology, showed that the biochemical relapse-free, but not overall survival (OS), at 90 months was significantly better with the hypofractionated (53%)...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.